公开(公告)号：US20220387636A1

公开(公告)日：2022-12-08

申请号：US17882708

申请日：2022-08-08

Applicant: OSAKA UNIVERSITY

Inventor： Koichi FUKASE ,  Atsushi SHINOHARA ,  Yoshikatsu KANAI ,  Kazuya KABAYAMA ,  Kazuko KANEDA ,  Zijian ZHANG ,  Jun HATAZAWA ,  Yoshifumi SHIRAKAMI ,  Atsushi SHIMOYAMA ,  Yoshiyuki MANABE

IPC: A61K51/04

Abstract: To develop a compound which is highly accumulated in cancer cells and capable of emitting an α-ray and provide a pharmaceutical composition for cancer treatment including the compound.
A pharmaceutical composition for cancer treatment including a compound having a structure in which 211At is introduced as a substituent into an amino acid derivative having an affinity with an amino acid transporter LAT1 or a pharmaceutically acceptable salt of the compound.

公开(公告)号：US20230233705A1

公开(公告)日：2023-07-27

申请号：US17925099

申请日：2021-05-14

Applicant: OSAKA UNIVERSITY

Inventor： Hiroki KATO ,  Koichi FUKASE ,  Kazuya KABAYAMA ,  Atsushi SHIMOYAMA ,  Yuichiro KADONAGA ,  Atsushi TOYOSHIMA ,  Atsushi SHINOHARA ,  Yasufumi KANEDA ,  Tomoyuki NISHIKAWA

IPC: A61K47/69 ,  A61P35/00 ,  A61P25/00 ,  A61K41/00 ,  A61P1/18

CPC classification number: A61K47/6923 ,  A61K47/6935 ,  A61P35/00 ,  A61P25/00 ,  A61K41/0038 ,  A61P1/18

Abstract: The present invention relates to a gold nanoparticle-containing medicine, and a treatment of a proliferative disease using the medicine. The present invention also relates to a gold nanoparticle-containing medicine that is bound to an alpha radioactive nucleus, and a treatment of a proliferative disease using the medicine.

公开(公告)号：US20210000988A1

公开(公告)日：2021-01-07

申请号：US16979346

申请日：2019-02-22

Applicant: OSAKA UNIVERSITY

Inventor： Koichi FUKASE ,  Atsushi SHINOHARA ,  Yoshikatsu KANAI ,  Kazuya KABAYAMA ,  Kazuko KANEDA ,  Zijian ZHANG ,  Jun HATAZAWA ,  Yoshifumi SHIRAKAMI ,  Atsushi SHIMOYAMA ,  Yoshiyuki MANABE

IPC: A61K51/04 ,  A61P35/00

Abstract: To develop a compound which is highly accumulated in cancer cells and capable of emitting an α-ray and provide a pharmaceutical composition for cancer treatment including the compound.
A pharmaceutical composition for cancer treatment including a compound having a structure in which 211At is introduced as a substituent into an amino acid derivative having an affinity with an amino acid transporter LAT1 or a pharmaceutically acceptable salt of the compound.